Neosalus lotion, a non-steroidal anti-inflammatory prescription product that offers topical treatment for the management of skin disorders, including atopic dermatitis and allergic contact dermatitis, launched in US by Quinnova Pharmaceuticals, Inc, a wholly owned subsidiary of AmDerma, LLC.

Neosalus lotion, along with Neosalus foam and Neosalus cream, uses patented Proderm Technology to help provide skin barrier repair, protection, and hydration.

In addition, the Neosalus line of products is specially formulated with several key ingredients that can promote healthy skin: dimethicone to help restore the skin barrier and reduce trans-epidermal water loss (TEWL); glycerin, a humectant to help retain moisture; and stearic/palmitic acids to produce ceramides, cholesterol, and other free fatty acids in the ratio the skin needs.

All Neosalus products are non-comedogenic and petrolatum-free and do not contain steroids or alcohol. Multiple dosage forms offer several convenient options to meet patients' site-specific needs--Neosalus cream can be used to treat problem dry skin on the hands, face, and elbows; Neosalus foam is suited for hair-bearing skin on the chest, arms, and legs; and the new Neosalus lotion may be used for total body coverage, including the face.

The US therapeutic dermatology market, which focuses on disorders and diseases of the skin, mucous membrane, hair and nails, is expected to reach $8.9 billion by 2013 due to the often chronic nature of these diseases.